Key points from article :
Danish biotech Vesper Bio received a $873,000 grant from The Michael J Fox Foundation to study sortilin inhibitors in Parkinson's disease.
Sortilin is a protein linked to brain function, and Vesper's drugs aim to boost progranulin levels, which are thought to be important for brain health.
Vesper's lead drug, VES001, is a pill that can cross the blood-brain barrier and potentially help patients with rapidly declining mental function.
This research could lead to new treatments for Parkinson's and other brain diseases, although it's still in early stages.
It could offer new hope for people with Parkinson's.
Vesper is also developing VES001 for another brain disease called Frontotemporal Dementia and preparing another drug for a different brain condition.
